This paper summarizes the findings of an industry panel study evaluating how new Autonomous Intelligence technologies, such as artificial intelligence and machine learning, impact the system and operational architecture of supply chain control tower (CT) implementations that serve the pharmaceutical industry. Such technologies can shift CTs to a model in which real-time information gathering, analysis, and decision making are possible. This can be achieved by leveraging these technologies to better manage decision complexity and execute decisions at levels that cannot otherwise be managed easily by humans. Some of the key points identified are in the areas of the fundamental capabilities that need to be supported and the improved level of decision visibility that they provide. We also consider some the challenges in achieving this, which include data quality and integrity, collaboration and data sharing across supply chain tiers, cross-system interoperability, decision-validation and organizational impacts, among others.
Introduction
Today's pharmaceutical distributors are faced with several key strategic priorities.
These include retaining and managing operating margin, acquiring business agility and controlling pharmaceutical counterfeiting and fraud. Overall, the control tower (CT) concept can transform how healthcare and pharma industries lead and manage their supply chains by shifting to a model in which real-time information gathering, analysis, and decision making are possible. In essence, a CT is a center of excellence that facilitates a coordinated network to continuously manage complexity and execute at levels that cannot otherwise be managed easily by humans. It must provide fundamental capabilities to enable the levels of visibility and awareness to achieving this mission (1) .
This research was a result of an industry study whereby a panel of experts was assembled to derive an accelerated view on the future of control tower supply chain capabilities within the pharmaceutical industry. The emphasis of the study was to determine what form the CT of the future would take, and to identify those areas within the CT framework that would be most fertile for application of forwardlooking Autonomous Intelligence (AI) related technologies. A range of needs was explored by obtaining unique perspectives from the panel, representing the entire pharmaceutical value chain, including those from academic, manufacturing, distribution, pharmacy and technology fields, as well as other key players in the ecosystem (2).
Today's CT solutions provide somewhat simplistic, limited operational views while claiming end to end visibility, providing a window into certain parts of the supply chain at the expense of others (3) . Ultimately, visibility boils down to the execution of orders while balancing costs and availability to satisfy contracts and customer demand. In this respect, the CT should provide a holistic end-to-end view across supply chain suppliers, contract manufacturers, transportation carriers, and third-party logistic vendors to track the active movements of goods from origin to destination (4) . To this end, the panel explored the common levels of visibility that are required by pharmaceutical distributors and the degree of visibility needed both now and within the future, with the understanding that visibility can vary relative to the supply chain tier, type of supplier and type product or product group.
Overall, a CT serves as a command center to enable a firm to act more closely with suppliers and be more proactively provide customer service, and ultimately improve profitability. 
Fundamental CT Capabilities
The CT must provide capabilities that are shared across supply chain players and third-party providers.
These include: (9) . This is becoming more common in the healthcare and medical technology fields.
Industry Trends Influencing Visibility
Several key industry trends were identified that are driving the overarching visibility requirements of the CT:


End-to-end patient care:
This trend is motivating partnerships among logistics firms, pharmaceutical producers, and local pharmacists to form powerful interconnected patient centric networks that are demand driven so that patients can obtain what they need and when they need it (10).

Direct to consumer:
Large pharmaceutical distributors are moving towards a direct to consumer model, competing with entities such as Walgreens.

Competitive threats from expert supply chains:
Strong partnerships are emerging in order to improve visibility and cooperation across the network, involving players such as Amazon.
While the primary goal is to serve the patient, they must create higher value services and with lower costs, year after year, to offset constantly low margins. The pharmaceutical distributor will have constantly changing needs for CT visibility. At the core of visibility is the information linked to physical product movements. 
Information Flows and Channels
Information is the media that enables visibility for the CT. There are three classes of information that were identified as necessary to underpin visibility: require product serialization to support these capabilities.
Upstream Flows
Upstream flows entail a tremendous amount of information from the manufacturer to the distributor.
Such information can impact inventory planning at the main procurement centers and down through the enterprise to numerous regional distribution centers.
Because of the nature of the bullwhip effect, it is easier to manage information and visibility going upstream, although the impact in inventory and cost is larger. upstream at the point of production (desired).
Downstream Flows
Downstream information flows should be tailored based on the specific type of customer or contract (e.g. end-retailer, pharmacy, hospital, etc.).
Downstream players will require similar information provided to the distributor from the upstream path, but in a different format depending on the contract being administered to that specific provider or retailer. 
CT Visibility Challenges
All of the above is not without challenge. Those challenges that were noted as being the most significant in limiting CT visibility include: 
Decision Capabilities
The supply chain CT must support decision-making and controls for operators in a pharmaceutical distribution environment. In addition to visibility and alerting capabilities, CTs must provide operators with the ability to make decisions and execute measures in response to operational performance issues and disruptions. In this respect, the following were some of the issues addressed in the study: 
Operational/Execution Level Capabilities
Tactical Level Capabilities
The CT must provide mid-level managers with decision level capabilities to devise short-term optimal courses of actions based on analysis of the supply chain's current operational picture. These would include the following capabilities: Enabling the ability to evaluate available options when forecasts are updated due to demand spikes or rush orders within the planning horizon.
At this level, technologies such as machine learning and/or AI could be useful.
CT Operative Model for AI
Effective CT implementation can present unique opportunities for driving supply chain strategies for business outcomes. These capabilities must afford executives with the following abilities: 
Technology Capabilities
The types of technologies that are best suited to support decision-making and response activities in the CT environment were explored. The technologies that are most applicable or promising for specific kinds of decisions or control actions at the operational, tactical or strategic level were conveyed, using specific examples of actual use cases of the technology and success stories and non-success stories. The technology and operational prerequisites were envisioned for enactment within a specific decision-making context, with emphasis on systems or other technologies that are needed to be in-place or available in order to support CT operations.
Technology Levels
There are three levels of basic technology pre-requisites for CT operation that were defined: Avoiding Pitfalls -Starting with a technology and using a "build it and they will come strategy" is rarely successful. While technology first strategies such as those seen in data lake, predictive, cognitive, or digitization implementations can receive strong executive sponsorship, they can be difficult to justify and have lengthy time-to-value, at which point they can be become outdated. Furthermore, requiring a sophisticated enterprise system with high data quality at the outset is expensive, can create risk and only delay implementation. 
Levels of Application for AI
Reliance on AI Technology for CT Decision Making
Decision technologies, such as machine learning and AI, can play an important role in supporting CT operations (19) . The level of reliance on these technologies for decision making was explored, with regard to how these technologies can be incorporated into CT decision functions at the operational, tactical and strategic levels, along with the level of data or information quality necessary for effective decision-making in order to use them. In addition to working with tangible data and information, the intangible information that needs to be captured by these decision technologies and how could it be captured was reviewed. The intention here was to arrive at a sense of the degree to which software/system vendors have been able to instill these capabilities within their CT solutions for effective decision making.
Implementation within
Decision-Making
The supply CT will rely on big data analytics to 
Applications of AI in the CT Environment
AI can thus play a valuable role in the decision-making processes within a CT environment.
Such decision-making requires learning based on high-quality transaction-based data, less tangible data and prior human-based operator decision behavior patterns. To this end, it would be desirable to know those supply chain functions that would be best applicable for 
Inventory Management
Risk management of inventory is another fertile area of application of AI. AI and machine learning based 
Master Scheduling
Organizational Reform
The supply chain professionals of the future will evolve from the management of exceptions to creating more strategic value through new ways of working. 
Data Sharing
If CMO data is incomplete, unavailable or wrong, CTs cannot make decisions and take action on the fly. 
Data Visibility
CMOs have a significant impact on CT upstream site-to-site and batch-to-batch data comparisons, data access, sharing, and retrieval, and quality assurance.
Furthermore, the methods used for KPI measurement and reporting output need to be agreed upon by the involved parties.
Conclusions
Today's CT solutions provide somewhat simplistic, 
